FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032020250> ?p ?o ?g. }

• W3032020250 endingPage "e16130" @default.
• W3032020250 startingPage "e16130" @default.
• W3032020250 abstract "e16130 Background: To observe the effect of adjuvant on the clinical efficacy and survival period of patients with liver cancer treated by UMIPIC (Ultra-minimum Incision personalized intratumoral chemoimmunotherapy). Methods: 156 liver cancer patients who were treated with UMIPIC with hapten or without hapten from January 2011 to December 2015 were selected for the study objects, including 124 cases with hapten as studying group and 32 cases without hapten as comparing group. All patients signed the treatment consent, treated according to the treatment guidelines of UMIPIC, followed up for the efficacy and the survival period of all patients more than 3 months, and observed whether there was effect on the clinical efficacy, adverse reactions, survival period and survival rate of patients with liver cancer patients treated with UMIPIC. Results: The common side effects of hapten group were fever 45.16%, pain 27.42%, hemoglobin reduction 14.78%, leucopenia 11.97%, thrombocytopenia 10.26%, liver function damage 5.26%, nausea 4.03%, renal dysfunction 2.61%. No rash, neurotoxicity and hair loss were found; The common adverse reactions in the non hapten group were fever 40.63%, pain 25.00%, hemoglobin reduction 17.24%, leucopenia 13.79%, thrombocytopenia 10.34%, nausea 6.25%. No other adverse reactions were found; there was no difference between the two groups (P > 0.05). The benefit rate of hapten group was 89.06% lower than that of non hapten group (94.74%) (P > 0.05). According to the follow-up results, the mean and median survival time of hapten group was 26.421 and 9.930 months, significantly higher than that of non hapten (16.473 and 7.230 months) (P < 0.05).The 1-year, 2-year, 3-year and 5-year survival rates of adjuvant group respectively were 45.69%, 33.33%, 25.68% and 20.83%,The 1-year, 2-year, 3-year and 5-year survival rates in the adjuvant free group respectively were 27.50%, 20.59%, 14.81% and 14.29%, The 1-year survival rate of hapten group was significantly higher than that of non hapten group (P < 0.05). Conclusions: There is no significant difference in the adverse reactions and clinical efficacy of UMIPIC in the treatment of liver cancer patients with and without hapten. Adding hapten can significantly prolong the survival time and improve the survival rate of patients with liver cancer patients treated with UMIPIC." @default.
• W3032020250 created "2020-06-05" @default.
• W3032020250 creator A5009343602 @default.
• W3032020250 creator A5010015600 @default.
• W3032020250 creator A5010190017 @default.
• W3032020250 creator A5014534582 @default.
• W3032020250 creator A5016050402 @default.
• W3032020250 creator A5020368695 @default.
• W3032020250 creator A5033999910 @default.
• W3032020250 creator A5052137925 @default.
• W3032020250 creator A5056763730 @default.
• W3032020250 creator A5063091229 @default.
• W3032020250 creator A5088279819 @default.
• W3032020250 creator A5091419308 @default.
• W3032020250 date "2020-05-20" @default.
• W3032020250 modified "2023-09-25" @default.
• W3032020250 title "The effect of hapten on the clinical efficacy and survival of patients with liver cancer treated by UMIPIC." @default.
• W3032020250 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e16130" @default.
• W3032020250 hasPublicationYear "2020" @default.
• W3032020250 type Work @default.
• W3032020250 sameAs 3032020250 @default.
• W3032020250 citedByCount "0" @default.
• W3032020250 crossrefType "journal-article" @default.
• W3032020250 hasAuthorship W3032020250A5009343602 @default.
• W3032020250 hasAuthorship W3032020250A5010015600 @default.
• W3032020250 hasAuthorship W3032020250A5010190017 @default.
• W3032020250 hasAuthorship W3032020250A5014534582 @default.
• W3032020250 hasAuthorship W3032020250A5016050402 @default.
• W3032020250 hasAuthorship W3032020250A5020368695 @default.
• W3032020250 hasAuthorship W3032020250A5033999910 @default.
• W3032020250 hasAuthorship W3032020250A5052137925 @default.
• W3032020250 hasAuthorship W3032020250A5056763730 @default.
• W3032020250 hasAuthorship W3032020250A5063091229 @default.
• W3032020250 hasAuthorship W3032020250A5088279819 @default.
• W3032020250 hasAuthorship W3032020250A5091419308 @default.
• W3032020250 hasConcept C121608353 @default.
• W3032020250 hasConcept C126322002 @default.
• W3032020250 hasConcept C159654299 @default.
• W3032020250 hasConcept C197934379 @default.
• W3032020250 hasConcept C203014093 @default.
• W3032020250 hasConcept C2778570526 @default.
• W3032020250 hasConcept C2780580376 @default.
• W3032020250 hasConcept C29144244 @default.
• W3032020250 hasConcept C71924100 @default.
• W3032020250 hasConcept C90924648 @default.
• W3032020250 hasConceptScore W3032020250C121608353 @default.
• W3032020250 hasConceptScore W3032020250C126322002 @default.
• W3032020250 hasConceptScore W3032020250C159654299 @default.
• W3032020250 hasConceptScore W3032020250C197934379 @default.
• W3032020250 hasConceptScore W3032020250C203014093 @default.
• W3032020250 hasConceptScore W3032020250C2778570526 @default.
• W3032020250 hasConceptScore W3032020250C2780580376 @default.
• W3032020250 hasConceptScore W3032020250C29144244 @default.
• W3032020250 hasConceptScore W3032020250C71924100 @default.
• W3032020250 hasConceptScore W3032020250C90924648 @default.
• W3032020250 hasIssue "15_suppl" @default.
• W3032020250 hasLocation W30320202501 @default.
• W3032020250 hasOpenAccess W3032020250 @default.
• W3032020250 hasPrimaryLocation W30320202501 @default.
• W3032020250 hasRelatedWork W2332114612 @default.
• W3032020250 hasRelatedWork W2343034073 @default.
• W3032020250 hasRelatedWork W2347967707 @default.
• W3032020250 hasRelatedWork W2350328551 @default.
• W3032020250 hasRelatedWork W2357025913 @default.
• W3032020250 hasRelatedWork W2361331986 @default.
• W3032020250 hasRelatedWork W2581074245 @default.
• W3032020250 hasRelatedWork W2767267017 @default.
• W3032020250 hasRelatedWork W2888625382 @default.
• W3032020250 hasRelatedWork W4313236518 @default.
• W3032020250 hasVolume "38" @default.
• W3032020250 isParatext "false" @default.
• W3032020250 isRetracted "false" @default.
• W3032020250 magId "3032020250" @default.
• W3032020250 workType "article" @default.